Evaluation of factors affecting mortality in patients with idiopathic pulmonary fibrosis

Creative Commons License

Argun Barış S., Önyılmaz T., Öztürk B. G., Öksüzler Kızılbay G., Selvi Güldiken G., Boyacı H., ...Daha Fazla

European Respiratory Society Congress, Amsterdam, Hollanda, 27 Eylül - 01 Ekim 2025, cilt.66, ss.5083, (Özet Bildiri)

  • Yayın Türü: Bildiri / Özet Bildiri
  • Cilt numarası: 66
  • Doi Numarası: 10.1183/13993003.congress-2025.pa5083
  • Basıldığı Şehir: Amsterdam
  • Basıldığı Ülke: Hollanda
  • Sayfa Sayıları: ss.5083
  • Kocaeli Üniversitesi Adresli: Evet

Özet

Introduction and Objective: Idiopathic pulmonary fibrosis (IPF) has high mortality, with average survival of 2–3 years without treatment. This study aimed to determine the frequency and factors affecting mortality in IPF patients.

Methods: The demographics, pulmonary function test, laboratory results, clinical outcomes and mortality data of the IPF patients were recorded retrospectively.

Results: The study included 268 patients (22.8% women, 77.2% men) with median age of 72 years. Antifibrotic treatment was initiated in 70.2% of patients. 14.8% had an exacerbation, and 40.3% had a history of hospitalization. The overall mortality rate was 44% (n=118), with median survival of 29.5 months. The mortality group had higher age (p<0.001), and higher rates of coronary artery disease (p=0.023), pulmonary embolism (p=0.005), pulmonary hypertension (p<0.001), and malignancy (p=0.01). No significant difference was observed in treatment use and type of antifibrotic therapy. Exacerbations (p=0.001) and hospitalization frequency (p<0.001) were significantly higher in mortality group. GAP score (OR:11.68, 95%CI:2.63–51.88, p=0.001), pulmonary hypertension (OR:15.39, 95%CI:1.54–153.67, p=0.02), exacerbation (OR:56.2, 95%CI:1.22–2585.8, p=0.039), baseline FVC value (OR:1.103, 95%CI:1.014–1.2, p=0.022), mean platelet volume (MPV) (OR:0.29, 95%CI:0.11–0.74, p=0.01), and AST (OR:1.124, 95%CI:1.005–1.26, p=0.04) were the independent risk factors associated with mortality. Conclusion:Despite advancements in diagnosis and treatment, IPF remains a disease with high mortality. Preventing exacerbations, minimizing pulmonary function decline, and managing comorbidities are expected to reduce mortality.